The tweet was deleted by the author.
But we saved everything 🙂.
Altimmune has announced the completion of enrollment for its RECLAIM Phase 2 trial focused on alcohol use disorder (AUD).
This marks a significant step forward in advancing their research in this crucial area of public health. The company has expressed eagerness to continue progressing with the study and aims to share topline data from the trial by 2026. Such trials are essential in understanding and developing new treatments for alcohol use disorder, which affects millions worldwide.
The RECLAIM trial represents a part of Altimmune's broader commitment to innovative medical solutions.
Altimmune’s progress in developing treatments for alcohol use disorder underscores its active role in shaping the future of metabolic and liver health therapies. This continued commitment reflects themes discussed in the company’s collaboration with industry experts to examine the evolving MASH landscape, as explored in recent analyses of emerging approaches and challenges within the sector.